NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. Analytics refer to sales of drugs used in the direct treatment of severe sepsis/septic shock. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 33 companies including many key and niche players such as Agennix AG, AstraZeneca Plc, Artisan Pharma, Atox Bio, Inc., CytoGenix, Inc., Chong Kun Dang Pharmaceutical Corporation, Daiichi-Sankyo Company, Ltd., Endacea, Inc., Eli Lilly and Company, Medinox, Inc., and NexBio, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 4
A Prelude 4
Table 1: Annual Incidence of Sepsis in the US and EU-27 5
Sepsis Treatment: An Untapped Market 5
Challenges Facing Sepsis Treatment 5
Lack of Awareness
Copyright©2010 PR Newswire.
All rights reserved